DBV Technologies S.A. (DBVT) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Kura Oncology (KURA) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 7.7% versus a loss of 46.6%. Over five years, DBVT leads with a -18.0% price change compared with -48.3% for KURA. Kura Oncology is the larger company by market cap ($807.8 million vs $568.8 million), about 1.4 times the size, while DBV Technologies S.A. is growing revenue faster (+35.8% vs +25.2%).
Kura Oncology converts more of its revenue into profit, with a net margin of -412.9% versus -2607.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | KURA |
|---|---|---|
| Share price | $9.05 | $9.08 |
| Market cap | $568.78M | $807.76M |
| 1-day change | -0.66% | -6.39% |
| YTD return | -52.79% | -12.61% |
| 1-year return | -46.61% | -7.72% |
| 5-year return | -18.03% | -48.29% |
| EPS (TTM) | $-3.50 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | $67.48M |
| Revenue growth (YoY) | +35.77% | +25.24% |
| Net income (latest FY) | $-146.95M | $-278.67M |
| Operating margin | -2609.23% | -449.94% |
| Net margin | -2607.29% | -412.95% |
| 52-week high | $26.19 | $13.90 |
| 52-week low | $8.63 | $7.36 |
| Distance from 52-week high | -65.44% | -34.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +328.07% | +250.77% |
| Average volume | 350.73K | 1.82M |
| Shares outstanding | 62.85M | 88.96M |
| Employees | 170 | 260 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KURA has outperformed DBVT by 38.9 percentage points over the past year.
- Kura Oncology is more profitable, keeping -412.9 cents of every revenue dollar as net income versus -2607.3 cents for DBV Technologies S.A..
- DBV Technologies S.A. grew revenue faster in its latest fiscal year (+35.77% vs +25.24%).
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Healthcare · Biotechnology · 260 employees
DBVT vs KURA FAQ
Which is bigger, DBV Technologies S.A. or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $568.78M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or KURA?
KURA returned -7.72% over the past 12 months, compared with -46.61% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.